Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A multi-center study of a machine learning algorithm for identifying undiagnosed patients with myelodysplastic syndrome based on complete blood count data

Anna Lason, Arkadiusz Sycz, Karol Lis, Patryk Weglarz, Lukasz Szukalski, Natalia Leonczuk, Szymon Fornagiel, Grzegorz Helbig, Marta Sobas, Jaroslaw Piszcz, Łukasz Brodowski, Agnieszka Pluta, Krzysztof Madry, Grzegorz Basak, Michal J. Dabrowski, Marek Dudziński

Blood (2025) 146 (Supplement 1): 5629.

https://doi.org/10.1182/blood-2025-5629

Published: 2025

Journal Articles

Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group

Grzegorz Charlinski, Jacek Krzanowski, Dominik Gorzelak, Agata Tyczynska, Lukasz Szukalski, Magdalena Olszewska-Szopa, Pawel Steckiewicz, Sylwia Trzpiot, Agnieszka Druzd-Sitek, Jaroslaw Grzyb, Anna Kopinska, Agnieszka Szymczyk, Boguslaw Machalinski, Elzbieta Wiater, Michał Mielnik, Marek Rodzaj, Marek Hus, David Vesole, Artur Jurczyszyn

Blood (2025) 146 (Supplement 1): 5838.

https://doi.org/10.1182/blood-2025-5838

Published: 2025

Journal Articles

Real-world application of AI in expediting paroxysmal nocturnal hemoglobinuria diagnosis

Blood (2025) 146 (Supplement 1): 1415.

https://doi.org/10.1182/blood-2025-1415

Published: 2025

Journal Articles

AI-powered precision: Unmasking hidden treatment optimizations for lower-risk myelodysplastic syndrome patients based on real-world, multi center EHR data.

Marek Dudziński, Anna Lason, Arkadiusz Sycz, Patryk Weglarz, Natalia Leonczuk, Lukasz Szukalski, Szymon Fornagiel, Grzegorz Helbig, Jaroslaw Piszcz, Marta Sobas, Agnieszka Pluta, Krzysztof Madry, Łukasz Brodowski, Grzegorz Basak, Michal J. Dabrowski, Karol Lis

Blood (2025) 146 (Supplement 1): 6209.

https://doi.org/10.1182/blood-2025-6209

Published: 2025

Journal Articles

Artificial Intelligence-Based Algorithm for the Diagnosis of Idiopathic Multicentric Castleman's Disease in a Lower-Middle Income Country

Antonio Adolfo Guerra Soares Brandão, Danielle Leão Cordeiro De Farias, Michał Konopelko, Wojciech Amtmański, Mikolaj Mroz, Aleksandra Jurczuk, Maciej Majewski, Lukasz Szukalski, Grzegorz Basak, Bianca Milena Verboski, Caio Lopes de Assunção, Karol Lis, Michal Jerzy Dabrowski, Marek Dudziński

Blood (2024) 144 (Supplement 1): 7623.

https://doi.org/10.1182/blood-2024-198242

Published: 2024

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Blood (2023) 142 (Supplement 1): 340.

https://doi.org/10.1182/blood-2023-190209

Published: 2023

Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Blood (2023) 142 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2023-189537

Published: 2023

Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2023) 142 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2023-189850

Published: 2023

Journal Articles

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, Marta Sobas, Parvis Sadjadian, Natalia Curto-Garcia, Lee-Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Tudor Zdrenghea, Laurence Legros, Francois Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloe James, Rajko Kusec, Marie Lauermannova, Maria Soledad Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora-Tybor, Kamel Laribi, Anna Kulikowska De Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek C. Skoda, Stephane Giraudier, Martin Griesshammer, Jean-Jacques Kiladjian, Claire N Harrison

Blood (2023) 142 (Supplement 1): 748.

https://doi.org/10.1182/blood-2023-185108

Published: 2023

Journal Articles

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Blood (2018) 132 (Supplement 1): 4452.

https://doi.org/10.1182/blood-2018-99-115971

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A multi-center study of a machine learning algorithm for identifying undiagnosed patients with myelodysplastic syndrome based on complete blood count data

Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group

Real-world application of AI in expediting paroxysmal nocturnal hemoglobinuria diagnosis

AI-powered precision: Unmasking hidden treatment optimizations for lower-risk myelodysplastic syndrome patients based on real-world, multi center EHR data.

Artificial Intelligence-Based Algorithm for the Diagnosis of Idiopathic Multicentric Castleman's Disease in a Lower-Middle Income Country

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only